These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8096292)

  • 1. Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
    van Dissel JT; van Furth R; Compier BA; Feuth HD; Frolich M
    Lancet; 1993 Apr; 341(8850):959-60. PubMed ID: 8096292
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
    McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
    Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possibilities of immunoprophylaxis and immunotherapy in gut-derived infectious-toxic shock (GITS).
    Imbach P; Hässig A; Cottier H
    Curr Stud Hematol Blood Transfus; 1992; (59):301-23. PubMed ID: 1572217
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monoclonal antibodies in the treatment of septic shock].
    Trilla A; Alonso P
    Med Clin (Barc); 1992 Dec; 99(20):778-80. PubMed ID: 1460950
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiendotoxin antibodies: a dead end?
    Cross AS
    Ann Intern Med; 1994 Jul; 121(1):58-60. PubMed ID: 8198349
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapies directed against endotoxin--has the time come?
    Quezado ZM; Hoffman WD
    West J Med; 1993 Apr; 158(4):424-5. PubMed ID: 8317138
    [No Abstract]   [Full Text] [Related]  

  • 9. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
    Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
    JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiendotoxin antibodies.
    Siegel JP
    Ann Intern Med; 1995 Feb; 122(4):315-6. PubMed ID: 7825773
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
    Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
    J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody to endotoxin in the treatment of gram-negative sepsis.
    McCabe WR
    JAMA; 1992 May; 267(17):2325; author reply 2326. PubMed ID: 1564763
    [No Abstract]   [Full Text] [Related]  

  • 15. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New strategies in nonantibiotic treatment of gram-negative sepsis.
    Cohn J; Bone RC
    Cleve Clin J Med; 1992; 59(6):608-15. PubMed ID: 1424072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody to endotoxin in the treatment of gram-negative sepsis.
    van Deventer S
    JAMA; 1992 May; 267(17):2325-6. PubMed ID: 1564765
    [No Abstract]   [Full Text] [Related]  

  • 18. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.